000			01783 a2200481 4500
005			20250517235237.0
264		0	_c20181127
008			201811s 0 0 eng d
022			_a1790-6245
024	7		_a10.21873/cgp.20095 _2doi
040			_aNLM _beng _cNLM
100	1		_aTran, Ha Vu
245	0	0	_aCopy Number Alterations in Tumor Genomes Deleting Antineoplastic Drug Targets Partially Compensated by Complementary Amplifications. _h[electronic resource]
260			_bCancer genomics & proteomics _c
300			_a365-378 p. _bdigital
500			_aPublication Type: Journal Article
650	0	4	_aAntineoplastic Agents _xadverse effects
650	0	4	_aAxitinib
650	0	4	_aCarcinoma, Renal Cell _xdrug therapy
650	0	4	_aDNA Copy Number Variations _xgenetics
650	0	4	_aDrug Resistance, Neoplasm _xgenetics
650	0	4	_aFemale
650	0	4	_aGenome, Human _xdrug effects
650	0	4	_aGlioblastoma _xdrug therapy
650	0	4	_aHumans
650	0	4	_aImidazoles _xtherapeutic use
650	0	4	_aIndazoles _xtherapeutic use
650	0	4	_aIndoles _xtherapeutic use
650	0	4	_aMale
650	0	4	_aMolecular Targeted Therapy
650	0	4	_aNiacinamide _xanalogs & derivatives
650	0	4	_aPhenylurea Compounds _xtherapeutic use
650	0	4	_aPyrroles _xtherapeutic use
650	0	4	_aSorafenib
650	0	4	_aSunitinib
650	0	4	_aVascular Endothelial Growth Factor Receptor-1 _xgenetics
650	0	4	_aVascular Endothelial Growth Factor Receptor-3 _xgenetics
650	0	4	_afms-Like Tyrosine Kinase 3 _xgenetics
700	1		_aKiemer, Alexandra K
700	1		_aHelms, Volkhard
773	0		_tCancer genomics & proteomics _gvol. 15 _gno. 5 _gp. 365-378
856	4	0	_uhttps://doi.org/10.21873/cgp.20095 _zAvailable from publisher's website
999			_c28814728 _d28814728